GlassScriptPhysician profile
Karen Gordon
NPI 1770555856
$18,699.92
in general payments reported to CMS, 2019-2025
37 companies · $3,947 in 2025
The $3,947 reported for 2025 was more than what 88% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,327 · 2020: $1,037 · 2021: $2,275 · 2022: $3,674 · 2023: $3,155 · 2024: $3,286 · 2025: $3,947.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,020.38 |
| Education | $366.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,132.61 | 2019-2025 | |
| Lilly USA, LLC | $1,955.78 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| Amgen INC. | $1,912.43 | 2020-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $1,509.38 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Pfizer INC. | $1,446.94 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $941.63 | 2019-2025 | Cabtreo, Jublia, Arazlo |
| Sun Pharmaceutical Industries INC. | $927.58 | 2019-2025 | Absorica Ld, Winlevi, Blu-U |
| Novartis Pharmaceuticals Corporation | $918.55 | 2019-2025 | |
| Leo Pharma INC. | $887.31 | 2019-2024 | Adbry |
| Arcutis Biotherapeutics, INC. | $837.61 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $765.73 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $659.50 | 2020-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $606.58 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Incyte Corporation | $542.51 | 2022-2025 | Opzelura |
| Dermavant Sciences, INC. | $388.85 | 2022-2024 | Vtama |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $299.48 | 2019-2025 | Bimzelx, Cimzia |
| Vyne Pharmaceuticals INC. | $280.40 | 2020-2021 | |
| Journey Medical Corporation | $279.01 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $244.35 | 2022-2025 | Spevigo |
| Genzyme Corporation | $210.29 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $159.38 | 2019-2025 | |
| Epi Health, LLC | $154.21 | 2019-2022 | |
| Lnhc, INC | $135.81 | 2025 | Zelsuvmi |
| Kyowa Kirin, INC. | $132.94 | 2023-2024 | Poteligeo |
| Dermira, INC. | $74.09 | 2019 | |
| Botanix Sb INC | $72.07 | 2025 | Sofdra |
| Organon LLC | $52.91 | 2025 | Vtama |
| Celgene Corporation | $42.21 | 2019 | |
| Almirall LLC | $16.99 | 2021 | |
| Mission Pharmacal Company | $15.94 | 2020 | |
| Blueprint Medicines Corporation | $15.30 | 2025 | Ayvakit |
| Genentech USA, INC. | $14.32 | 2022 | |
| Biofrontera INC. | $14.06 | 2020 | |
| Dusa Pharmaceuticals, INC. | $13.50 | 2019 | |
| Merck Sharp & Dohme LLC | $13.50 | 2019 | |
| Promius Pharma LLC | $13.17 | 2019 | |
| Glenmark Therapeutics INC. | $13.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.